|
CAUSE INCREASED SERUM LEVELS OF PROCAINAMIDE, SO START THERAPY WITH LOWER DOSE
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
PROLONG QT INTERVAL; CO-ADMINISTRATION WITH CLASS 1A ANTIARRHYTHMIC AGENTS SHOULD BE AVOIDED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCOMITANT USE SHOULD BE AVOIDED
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
ALCOHOL ACCELERATE THE METABOLISM OF THE DRUG BY LIVER BY INDUCING HEPATIC ENZYMES
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TRIMETHOPRIM DECREASES RENAL CLEARANCE OF THE DRUG
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|